Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genmab, Medarex swap assets

Genmab (CSE:GEN) and Medarex (MEDX) exchanged assets that had been co-owned by the companies, including a therapeutic MAb

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE